Remission induction in acute myeloid leukemia

International Journal of Hematology

Volumn 96, Issue 2, 2012, Pages 164-170

  Stein, Eytan M ^a   Tallman, Martin S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Remission

Indexed keywords

CLADRIBINE; CYTARABINE; DAUNORUBICIN; ERLOTINIB; FLUDARABINE; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARDIOTOXICITY; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE MUTATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION;

EID: 84866990365     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1121-y     Document Type: Article

References (11)

1. Preisler H, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987;69(5):1441-9.
2. Yates J, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60(2):454-62.
3. Rai KR, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58(6):1203-12.
4. Fernandez HF, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-59.
5. Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12): 1079-89.
6. Lowenberg B, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13): 1235-48.
7. Lee JH, et al. A randomized trial comparing standard versus highdose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118(14):3832-41.
8. Ohtake S, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117(8):2358-65.
9. Holowiecki J, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012.
10. Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-77.
11. Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA- 0701): a randomised, open-label, phase 3 study. Lancet. 2012;379 (9825):1508-16.